WO2006042103A3 - Reversible inhibitors of cathepsin b - Google Patents

Reversible inhibitors of cathepsin b

Info

Publication number
WO2006042103A3
WO2006042103A3 PCT/US2005/036127 US2005036127W WO2006042103A3 WO 2006042103 A3 WO2006042103 A3 WO 2006042103A3 US 2005036127 W US2005036127 W US 2005036127W WO 2006042103 A3 WO2006042103 A3 WO 2006042103A3
Authority
WO
WIPO (PCT)
Prior art keywords
cathepsin
reversible inhibitors
inhibitors
compounds
directed
Prior art date
Application number
PCT/US2005/036127
Other languages
French (fr)
Other versions
WO2006042103A2 (en
Inventor
James T Palmer
Robert M Rydzewski
Original Assignee
Axys Pharm Inc
James T Palmer
Robert M Rydzewski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc, James T Palmer, Robert M Rydzewski filed Critical Axys Pharm Inc
Publication of WO2006042103A2 publication Critical patent/WO2006042103A2/en
Publication of WO2006042103A3 publication Critical patent/WO2006042103A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

The present invention is directed to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6a are as that are inhibitors of cathepsin B and are as in the description, that are inhibitors of cathepsin B and are therefore useful in treating diseases, disorders, or syndromes mediated by this cathepsin. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
PCT/US2005/036127 2004-10-05 2005-10-05 Reversible inhibitors of cathepsin b WO2006042103A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61641704P 2004-10-05 2004-10-05
US60/616,417 2004-10-05

Publications (2)

Publication Number Publication Date
WO2006042103A2 WO2006042103A2 (en) 2006-04-20
WO2006042103A3 true WO2006042103A3 (en) 2006-06-15

Family

ID=36084189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036127 WO2006042103A2 (en) 2004-10-05 2005-10-05 Reversible inhibitors of cathepsin b

Country Status (1)

Country Link
WO (1) WO2006042103A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR101462891B1 (en) 2006-12-14 2014-11-19 얀센 파마슈티카 엔.브이. Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US20020086996A1 (en) * 1999-03-15 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
WO2004026851A1 (en) * 2002-09-20 2004-04-01 Axys Pharmaceuticals, Inc. 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US20020086996A1 (en) * 1999-03-15 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
WO2004026851A1 (en) * 2002-09-20 2004-04-01 Axys Pharmaceuticals, Inc. 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors

Also Published As

Publication number Publication date
WO2006042103A2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2006042103A3 (en) Reversible inhibitors of cathepsin b
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2006065686A3 (en) Spiro derivatives as lipoxygenase inhibitors
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
WO2007009109A3 (en) Antiviral compounds
HRP20110566T8 (en) Azaindoles useful as inhibitors of jak and other protein kinases
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2005076990A3 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC DATED 26.07.07

122 Ep: pct application non-entry in european phase

Ref document number: 05804434

Country of ref document: EP

Kind code of ref document: A2